Scibase Receives Initial Order For Clinical Study From Castle Biosciences
Reuters
Sep 23, 2025
Sept 23 (Reuters) - SciBase Holding AB (publ) :: *RECEIVES INITIAL ORDER FOR CLINICAL STUDY FROM CASTLE BIOSCIENCES *ORDER CONSISTS OF NEVISENSE GO AND ELECTRODES TO VALUE OF AROUND $0.8 MILLION OR APPROXIMATELY MSEK 8 (ADDS DROPPED WORDS)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.